Search company, investor...

Embolic Protection

Stage

Series D | Alive

Total Raised

$14.78M

Last Raised

$6.78M | 22 yrs ago

About Embolic Protection

Devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures. Acquired by Boston Scientific in 2001.

Headquarters Location

331 East Evelyn Avenue

Campbell, California, 94041,

United States

Missing: Embolic Protection's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Embolic Protection's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Embolic Protection News

Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement

Oct 19, 2022

Background Transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis can lead to embolization of debris. Capture of debris by devices that provide cerebral embolic protection (CEP) may reduce the risk of stroke. We randomly assigned patients with aortic stenosis in a 1:1 ratio to undergo transfemoral TAVR with CEP (CEP group) or without CEP (control group). The primary end point was stroke within 72 hours after TAVR or before discharge (whichever came first) in the intention-to-treat population. Disabling stroke, death, transient ischemic attack, delirium, major or minor vascular complications at the CEP access site, and acute kidney injury were also assessed. A neurology professional examined all the patients at baseline and after TAVR. Results A total of 3000 patients across North America, Europe, and Australia underwent randomization; 1501 were assigned to the CEP group and 1499 to the control group. A CEP device was successfully deployed in 1406 of the 1489 patients (94.4%) in whom an attempt was made. The incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group (2.3% vs. 2.9%; difference, −0.6 percentage points; 95% confidence interval, −1.7 to 0.5; P=0.30). Disabling stroke occurred in 0.5% of the patients in the CEP group and in 1.3% of those in the control group. There were no substantial differences between the CEP group and the control group in the percentage of patients who died (0.5% vs. 0.3%); had a stroke, a transient ischemic attack, or delirium (3.1% vs. 3.7%); or had acute kidney injury (0.5% vs. 0.5%). One patient (0.1%) had a vascular complication at the CEP access site. Conclusions Among patients with aortic stenosis undergoing transfemoral TAVR, the use of CEP did not have a significant effect on the incidence of periprocedural stroke, but on the basis of the 95% confidence interval around this outcome, the results may not rule out a benefit of CEP during TAVR. (Funded by Boston Scientific; PROTECTED TAVR ClinicalTrials.gov number, NCT04149535 .)

Embolic Protection Frequently Asked Questions (FAQ)

  • Where is Embolic Protection's headquarters?

    Embolic Protection's headquarters is located at 331 East Evelyn Avenue, Campbell.

  • What is Embolic Protection's latest funding round?

    Embolic Protection's latest funding round is Series D.

  • How much did Embolic Protection raise?

    Embolic Protection raised a total of $14.78M.

  • Who are the investors of Embolic Protection?

    Investors of Embolic Protection include ONSET Ventures and Boston Scientific.

  • Who are Embolic Protection's competitors?

    Competitors of Embolic Protection include Reva Medical, Broncus Medical, TriVascular Technologies, BaroSense, Micrus Endovascular and 12 more.

Compare Embolic Protection to Competitors

R
Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

X
XTENT

Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

N
Navis Medical

Navis is a Cleveland, Ohio based company that has developed the Variable Control Guidewire System, a guidewire technology that aims to improve endovascular navigation and eliminate or reduce the need for multiple catheters and guidewires required during invasive peripheral vascular procedures.

Veryan Medical Logo
Veryan Medical

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.

M
MitraLife

Developing minimally invasive methods and devices for treating congestive failure and cardiac valve diseasen(Acquired by ev3)

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.